Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients

Karmali, Reem; Paganessi, Laura A.; Frank, Robin R.; Jagan, Sucheta; Larson, Melissa L.; Venugopal, Parameswaran; Gregory, Stephanie A.; Christopherson, Kent W.

doi:10.1189/jlb.0612301

Cited by 14 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are discrepancies between studies in terms of serum levels of IFNγ in CLL patients: both increased 39 and decreased 43 concentrations in relation to healthy controls were reported. In our study, there was no difference in IFNγ serum level between CLL and control subjects.…”

Section: Discussionmentioning

confidence: 93%

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation

et al. 2016

View full text Add to dashboard Cite

Background: Vitamin D (VD) deficiency results in a worse prognosis in patients with chronic lymphocytic leukemia (CLL) and may affect the production of cytokines. Nonetheless, there is the lack of studies dealing with VD supplementation and its impact on chemokines in CLL patients. Aim: The primary endpoint of our interventional study was to evaluate the effect of cholecalciferol supplementation on serum chemokines levels in CLL patients. Materials and methods: Eighteen subjects with CLL were enrolled for the study. Six-month-long cholecalciferol supplementation was performed in CLL patients with serum 25-OH-D3 levels below 30 ng/ml. Cytokines levels were assessed at the beginning of the study and after 6 months. Baseline measurements of cytokines were compared to those in apparently healthy controls. Results: Increased levels of CCL2, CCL3, CCL4, CXCL8, CXCL10, TNFα, bFGF, G-CSF, and VEGF were found in CLL patients in comparison with the healthy controls. In the course of the VD supplementation a decrease in serum levels of chemokines CCL11, CCL3, and cytokine PDGF-BB was observed. The decrease of CCL11 was found in CLL patients on VD supplementation solely, whereas the decrease of CCL3 and PDGF-BB was observed in CLL subjects on both chemotherapy and VD supplementation. Conclusion: The VD supplementation may exert beneficial effect on chemokines levels in CLL patients with VD deficiency.

show abstract

Section: Discussionmentioning

confidence: 93%

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, in agreement with previous studies, we detected that the lower IL‐23 levels in children with acute leukemia at diagnosis were normalized at remission, possibly attributed to cytokine changes favouring immunosuppressive T cell response and downregulating the protective one. In leukemia, an altered microenvironment in BM, PB and lymphoid tissue results from the recruitment of specific T cell subgroups and stromal cells with shifts in cytokine production 36,42 43‐45 .…”

Section: Discussionmentioning

confidence: 99%

Low IL‐23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden

Zampogiannis

Piperi

Baka

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

IL‐23 is an IL‐12 cytokine family member with pleiotropic functions that regulates tumour growth in various cancer types, exhibiting both anti‐tumorigenic and pro‐tumorigenic properties. Preclinical studies have shown a potential anti‐leukemic action on childhood B‐ALL cells. The study involved 65 children with acute leukemia [59 patients with acute lymphoblastic leukemia (ALL) and 6 patients with acute myeloid leukemia (AML)] and 27 healthy controls. Using an enzyme‐linked immunosorbent assay, we aimed to determine the IL‐23 levels in the peripheral blood (PB) and bone marrow (BM) of patients at diagnosis and at the end of the induction therapy (EIT). PB IL‐23 levels were lower in leukemia patients compared to the healthy controls. In all acute leukemia patients, IL‐23 levels were significantly lower at diagnosis both in PB (P = .015) and in BM (P = .037) compared to the PB and BM concentrations at the EIT. The same pattern was present in both subgroups of ALL and AML patients. The high leukemic burden at diagnosis was related with lower IL‐23 levels, which were increased with the disease remission. Considering the anti‐leukemic potential of this cytokine, the elevation of the IL‐23 concentration at the disease remission indicates a beneficial role of IL‐23 in paediatric acute leukemia.

show abstract

“…Karmali et al [ 32 ] found in their study with 28 CLL patients that serum IL-23 and IL-17 levels were lower than healthy controls. As with IL-17 in CLL, the results of studies with IL-23 are also inconsistent.…”

Section: Discussionmentioning

confidence: 99%

IL-17 and IL-23 levels in patients with early-stage chronic lymphocytic leukemia

Bankır

Açık

2020

North Clin Istanbul

View full text Add to dashboard Cite

OBJECTIVE: Cytokines produced by bone marrow mesenchymal stem cells are important components of the tumor microenvironment in chronic lymphocytic leukemia (CLL). The roles of IL-17 and IL-23 in both autoimmune diseases and tumor growth have been demonstrated. The role of the IL-17/23 axis in apoptosis has also been demonstrated in studies. Autoimmune cytopenias are common in CLL. In this study, we aimed to compare IL-17/IL-23 levels in early-stage CLL patients with healthy controls. METHODS: After obtaining ethical approval from the local ethics committee, 22 patients with early-stage chronic lymphocytic leukemia and 21 healthy control groups were included in this study. IL-17 and IL-23 were analyzed using the enzyme-linked immunosorbent assay method. RESULTS: The findings showed that the median IL-23 level was lower in men in the chronic lymphocytic leukemia group than women. There was a positive correlation between IL-17 and IL-23 levels in both the control group and the chronic lymphocytic leukemia group. There was no significant correlation between stage and IL-17 and IL-23 levels in chronic lymphocytic leukemia patients. CONCLUSION: Results of studies conducted on IL-17 and/or IL-23 in chronic lymphocytic leukemia in the literature are not consistent. These inconsistent results can be explained by the fact that the immune system develops differently in each individual due to environmental factors, past infections, intestinal flora, vaccines, ethnicity, and even gender. Therefore, it can be hypothesized that the development and application of personalized immunotherapy strategies instead of standard therapy in chronic lymphocytic leukemia may increase therapeutic success rates.

show abstract

Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients

Cited by 14 publications

References 38 publications

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation

Low IL‐23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden

IL-17 and IL-23 levels in patients with early-stage chronic lymphocytic leukemia

Contact Info

Product

Resources

About